News Releases

November 12, 2026

Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise

November 10, 2026

Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference

November 4, 2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 30, 2026

Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

October 22, 2026

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

October 5, 2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 29, 2026

Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 8, 2026

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

September 4, 2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026

Vor Bio To Participate in Upcoming September Conferences